HC Wainwright Issues Positive Estimate for COLL Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities research analysts at HC Wainwright lifted their Q3 2025 EPS estimates for shares of Collegium Pharmaceutical in a report issued on Monday, March 24th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will post earnings per share of $1.75 for the quarter, up from their prior forecast of $1.61. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2025 earnings at $1.82 EPS, FY2025 earnings at $6.26 EPS and FY2026 earnings at $6.36 EPS.

A number of other research firms have also issued reports on COLL. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. Piper Sandler cut their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Stock Down 1.3 %

COLL opened at $29.56 on Thursday. The firm has a market cap of $930.73 million, a P/E ratio of 12.74 and a beta of 0.99. The business’s fifty day simple moving average is $30.43 and its 200 day simple moving average is $32.50. Collegium Pharmaceutical has a 52 week low of $27.28 and a 52 week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the transaction, the chief financial officer now directly owns 177,195 shares of the company’s stock, valued at $5,315,850. This trade represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,193 shares of company stock worth $3,243,594. 3.98% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. New Age Alpha Advisors LLC purchased a new stake in Collegium Pharmaceutical during the fourth quarter valued at about $40,000. TD Private Client Wealth LLC lifted its stake in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth about $72,000. KBC Group NV increased its position in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.